报价延迟最少15分钟:2026/04/18 03:05 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
2.92 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-2.20/-0.14
|
|
企业价值
6.73M
|
| 资产负债 |
|
每股账面净值
0.91
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
5.00K
|
|
每股收益
1.23
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| Alaunos Therapeutics Inc is a preclinical-stage biopharmaceutical company focused on the development of novel, orally administered small-molecule therapeutics for obesity and related metabolic disorders, such as metabolic dysfunction-associated steatotic liver disease (MASLD, a type of fatty liver disease). The program aims to develop a differentiated, non-hormonal, non-incretin approach, unlike hormone-based treatments like GLP-1 drugs. It has a single reportable and operating segment related to biopharmaceutical research and development. |
